An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120
about
Structure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeFunctional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individualsStructure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological TheoryMax Bergmann lecture protein epitope mimetics in the age of structural vaccinologyTransplanting supersites of HIV-1 vulnerability.Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Antibody Binding Selectivity: Alternative Sets of Antigen Residues Entail High-Affinity Recognition.Identification of Peptide Mimics of a Glycan Epitope on the Surface of Parasitic Nematode LarvaeMotif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.Synergism between a CD4-mimic peptide and antibodies elicited by a constrained V3 peptide.Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.Protein engineering strategies for the development of viral vaccines and immunotherapeutics.Basic research in HIV vaccinology is hampered by reductionist thinking.HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.Synthetic virus-like particles and conformationally constrained peptidomimetics in vaccine design.Tat peptide-calmodulin binding studies and bioinformatics of HIV-1 protein-calmodulin interactions.
P2860
Q27675260-829F6C26-EEA8-4C8B-8BA4-0D4E785360E8Q27677941-CFE449CD-EA26-459D-8CB5-45644F85EAEAQ28071559-710516C1-AEBD-4D3C-AC8E-7B7D7898C29BQ30155145-E10CEA98-FCE0-4F0C-9D2D-71B996BC1A34Q33854841-6155F9A3-3E89-483F-A024-ADA5FB9DE2EEQ34204047-8195387E-6742-4DB9-90D5-04340BF73684Q35858630-82E6462A-0833-4BBF-BC38-3AE1904CD497Q36118347-5681C9B9-5BAD-49FD-8357-1A5379C7DF28Q36249053-38F6DC66-16D0-44F9-9953-23E51A657542Q36384117-33285A2E-C73A-411A-BFC5-34B038D4726AQ36715717-99F938E4-6EB5-4493-B211-E8FC6BC37976Q36920319-5EBA5499-324D-49C9-AD76-89EABF6B9375Q37625877-756BAD94-ACCC-40ED-B6B1-B5C8464B753DQ38025633-A7F859DA-5A1A-464E-9078-2840AFD47D7CQ38665463-085EC5E1-292D-450D-AB25-7A9DCC6AE355Q40968142-2E3252B5-99BC-448F-9472-2B5F72936503Q45361823-4522A965-5EA3-43A1-BAE8-346CCCB121B6Q51570059-58D6B0A5-9C2D-49B0-9735-1B7349C67565
P2860
An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
An optimally constrained V3 pe ...... linear homolog or HIV-1 gp120
@ast
An optimally constrained V3 pe ...... linear homolog or HIV-1 gp120
@en
type
label
An optimally constrained V3 pe ...... linear homolog or HIV-1 gp120
@ast
An optimally constrained V3 pe ...... linear homolog or HIV-1 gp120
@en
prefLabel
An optimally constrained V3 pe ...... linear homolog or HIV-1 gp120
@ast
An optimally constrained V3 pe ...... linear homolog or HIV-1 gp120
@en
P2093
P2860
P1433
P1476
An optimally constrained V3 pe ...... linear homolog or HIV-1 gp120
@en
P2093
Adi Moseri
Boris Arshava
Fred Naider
Jacob Anglister
Subramanyam Tantry
P2860
P304
P356
10.1016/J.VIROL.2010.03.007
P407
P577
2010-03-26T00:00:00Z